Lestaurtinib, a staurosporine analog with a broad spectrum of activity against tyrosine kinases, including FLT3, failed to increase response rate and prolong OS when administrated after chemotherapy in AML patients in first relapse [55]. This evidence concerns the gene FLT3 and acute myeloid leukemia.